UK Regenerative Medicine Platform

What UK Regenerative Medicine Platform does

The UK Regenerative Medicine Platform (UKRMP) was a £42 million national research funding initiative established in 2013 by BBSRC, EPSRC, and MRC, operating under UK Research and Innovation (UKRI) to address translational challenges in regenerative medicine and accelerate the clinical delivery of regenerative medicine therapies. The platform coordinated interdisciplinary research across leading UK universities, serving academic researchers and institutions working on stem cell biology, engineered cell environments, smart materials, immunomodulation, and therapeutic delivery systems. UKRMP did not generate revenue through commercial activity; instead, it distributed government funding as grants to academic research institutions through a competitive, peer-reviewed application process managed by the MRC Molecular and Cellular Medicine team.

UKRMP was delivered in two distinct phases. UKRMP1 (2013-2018, £25 million) supported five interdisciplinary research hubs and five disease-focused projects: the cell behaviour, differentiation and manufacturing hub (University of Sheffield), the engineering and exploiting the stem cell niche hub (University of Edinburgh), the safety and efficacy imaging hub (University of Liverpool), the acellular approaches for therapeutic delivery hub (University of Nottingham), and the immunomodulation hub (King's College London). UKRMP2 (2018-2024, £17 million) consolidated the structure into three broader interdisciplinary hubs: pluripotent stem cells and engineered cells (University of Cambridge), engineered cell environment (University of Edinburgh), and smart materials (Imperial College London), supplemented by cross-cutting immunology and strategic projects.

UKRMP's go-to-market was a sales-led, government-funded model using UKRI's centralized funding finder portal and the seven research council networks to attract applications from UK academic researchers. The platform concluded its mission in 2024, publishing its end report documenting research outputs, resources, publications, and patents from the UKRMP2 hubs. The initiative has now ceased operations, with funding ended and the operating status recorded as closed.

Name

UK Regenerative Medicine Platform

Legal name

UK Regenerative Medicine Platform

Website

https://ukrmp.org.uk

Company type

Private

Founded year

2013

Operating status

Closed

Headcount range

11–50 employees

Short description

UKRMP was a £42 million UK government research funding initiative (2013-2024) under UKRI/BBSRC/EPSRC/MRC that distributed grants to university research hubs advancing regenerative medicine translation. The programme concluded in 2024.

Ownership category

akta.pro rank

Product category

Biomedical Research Funding

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Global Health Research, Clinical Trials & Product Development Partnerships (PDPs) (HLAJAOAM)

Keywords

• Regenerative medicine research
• Stem cell research
• Translational research funding
• Interdisciplinary research hubs
• Biomedical research grants

Headquarters

HQ city

Cambridge

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Others

Revenue model

1. Research Funding Distribution: UKRMP is a £42 million government-funded research initiative, not a revenue-generating entity. The platform distributes funding as grants to academic research institutions through competitive peer-reviewed processes across two funding phases.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

UKRMP was a £42 million UK government-funded research initiative that coordinated and funded interdisciplinary research hubs across UK universities to address translational challenges in regenerative medicine. It operated in two phases (UKRMP1: 2013-2018 with £25M and UKRMP2: 2018-2024 with £17M), supporting research hubs focused on stem cell biology, engineered cells, smart materials, immunomodulation, imaging technologies, and acellular therapeutic delivery.

Product overview

The UK Regenerative Medicine Platform (UKRMP) is a £42 million national research funding initiative established in 2013 by BBSRC, EPSRC and MRC, delivered in two phases (UKRMP1 from 2013-2018 with £25M funding and UKRMP2 from 2018-2024 with £17M funding). UKRMP comprises multiple interdisciplinary research hubs focused on addressing translational challenges in regenerative medicine. UKRMP1 supported five complementary research hubs covering cell behaviour and manufacturing, stem cell niche engineering, imaging technologies, therapeutic delivery, and immunomodulation. UKRMP2 represented a consolidated structure of three hubs focusing on pluripotent stem cells and engineered cells, engineered cell environment, and smart materials. The initiative concluded in 2024 after bringing together leading UK researchers to advance regenerative medicine therapies toward clinical application.

Differentiator

Problem solved

Functional benefit

Products and services

• UKRMP1 - Cell Behaviour, Differentiation and Manufacturing Hub
• UKRMP1 - Engineering and Exploiting the Stem Cell Niche Hub
• UKRMP1 - Safety and Efficacy Imaging Technologies Hub
• UKRMP1 - Acellular Approaches for Therapeutic Delivery Hub
• UKRMP1 - Immunomodulation Hub
• UKRMP2 - Pluripotent Stem Cells and Engineered Cells Hub
• UKRMP2 - Engineered Cell Environment Hub
• UKRMP2 - Smart Materials Hub

Quantifiable outcome

• £42 million total investment over 11 years (2013-2024) supporting 8 research hubs across two funding phases
• +2 more outcomes

Named customers7 records

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators4 records

Recent moves5 records

Expansion highlights2 records

Broad incumbents

• National Institutes of Health (NIH) – Common Fund: US federal biomedical research funder supporting large-scale, cross-cutting programmes analogous to UKRMP's hub structure. A much larger incumbent operating broadly across biomedical research including regenerative medicine.
• Innovate UK: UK's innovation agency, part of UKRI, which funds commercial R&D including life sciences. Operates more broadly across sectors but shares the same funding-distribution mechanics and translational aims with UKRMP.

Direct peers

• Cell and Gene Therapy Catapult: UK-based innovation and technology catapult focused on advancing cell and gene therapies toward commercial readiness, including regenerative medicine applications. Closest active UK comparator in mission and translational emphasis.
• California Institute for Regenerative Medicine (CIRM): California's state-level stem cell and regenerative medicine research funding agency, established in 2004 with multi-billion-dollar bond funding. Highly comparable to UKRMP in mission (translational regenerative medicine) and structure (funding interdisciplinary research hubs), though larger in scale and US-based.

Others

• Wellcome Trust: Major UK-based biomedical research charity funding discovery and translational research including stem cell biology. Comparable in scale and UK research-funding role but operates as an independent charity rather than government programme.

Regional players

• Horizon Europe – Health Cluster: EU-level multi-billion-euro research funding framework covering health R&D, including regenerative medicine. Comparable funding-mechanism role to UKRMP but operating across EU geographies rather than UK-only.
• Centre for Cell Manufacturing Ireland / NIBRT: Ireland-based cell and gene therapy manufacturing research and training centre. Operates a comparable cell-therapy manufacturing focus on a smaller scale, with emphasis on GMP manufacturing translation relevant to UKRMP's manufacturing hubs.

Emerging players

• Innovative Medicines Initiative (IMI / IHI): Public-private partnership funding translational biomedical research across Europe. Shares UKRMP's translational, partnership-based funding model, with stronger industry leverage but broader therapeutic scope.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights5 records

Customer concentration

• Xx.com/UKRMP_ECE
• YouTubeyoutube.com/@ukriforresearchers
• Facebookfacebook.com/weareUKRI
• LinkedInlinkedin.com/company/uk-research-and-innovation
• Instagraminstagram.com/weareukri

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about UK Regenerative Medicine Platform